ArticleBlood advances2018

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.

Anne Sophie Kubasch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.